Extended-Release Type 2 Diabetes Drug, ACTOplus met, Submitted for FDA Approval
ACTOplus met, a New Drug Application for an extended-release version of its type 2 diabetes drug would allow for once-daily dosing was submitted by Takeda Pharmaceutical Co.’s (4502.TO) U.S.
Extended-release metformin, one of the active ingredients in ACTOplus met XR, was developed by Andrx Corp.
Read more on The Diabetes Blog
You may also like to read
- Pfizer Receives FDA Approval for Exubera - First Inhalable Insulin for Controlling Type-1 and Type-2 Diabetes
- Akorn Receives FDA Approval for Glaucoma Treatment
- Allergan’s Intraocular Pressure Drug Lumigan Received FDA Approval
- GPs Treatment for Type 2 Diabetes Patients
- Drug Cocktail May Reverse Diabetes
